Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Multiple Sclerosis

  Free Subscription


18.03.2019

1 AJNR Am J Neuroradiol
2 Ann N Y Acad Sci
1 Ann Neurol
2 J Neuroimmunol
1 J Neurol
1 Nat Rev Neurol
7 Neurology
3 PLoS One
3 Rev Neurol


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    AJNR Am J Neuroradiol

  1. BERGSLAND N, Ramasamy D, Tavazzi E, Hojnacki D, et al
    Leptomeningeal Contrast Enhancement Is Related to Focal Cortical Thinning in Relapsing-Remitting Multiple Sclerosis: A Cross-Sectional MRI Study.
    AJNR Am J Neuroradiol. 2019 Mar 14. pii: ajnr.A6011. doi: 10.3174/ajnr.A6011.
    PubMed     Text format     Abstract available


    Ann N Y Acad Sci

  2. MOUMDJIAN L, Moens B, Vanzeir E, De Klerck B, et al
    A model of different cognitive processes during spontaneous and intentional coupling to music in multiple sclerosis.
    Ann N Y Acad Sci. 2019 Mar 13. doi: 10.1111/nyas.14023.
    PubMed     Text format     Abstract available

  3. RINALDI E, Consonni A, Guidesi E, Elli M, et al
    Gut microbiota and probiotics: novel immune system modulators in myasthenia gravis?
    Ann N Y Acad Sci. 2018;1413:49-58.
    PubMed     Text format     Abstract available


    Ann Neurol

  4. CREE BAC, Hollenbach JA, Bove R, Kirkish G, et al
    Silent Progression in Disease Activity-Free Relapsing Multiple Sclerosis.
    Ann Neurol. 2019 Mar 9. doi: 10.1002/ana.25463.
    PubMed     Text format     Abstract available


    J Neuroimmunol

  5. CIERNY D, Michalik J, Dubovan P, Skerenova M, et al
    The association of rs703842 variants in CYP27B1 with multiple sclerosis susceptibility is influenced by the HLA-DRB1*15:01 allele in Slovaks.
    J Neuroimmunol. 2019;330:123-129.
    PubMed     Text format     Abstract available

  6. AMMITZBOLL C, Bornsen L, Petersen ER, Oturai AB, et al
    Perfluorinated substances, risk factors for multiple sclerosis and cellular immune activation.
    J Neuroimmunol. 2019;330:90-95.
    PubMed     Text format     Abstract available


    J Neurol

  7. FRAU J, Coghe G, Lorefice L, Fenu G, et al
    Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis.
    J Neurol. 2019 Mar 12. pii: 10.1007/s00415-019-09272.
    PubMed     Text format     Abstract available


    Nat Rev Neurol

  8. FYFE I
    New rat model recapitulates disabling grey matter damage in multiple sclerosis.
    Nat Rev Neurol. 2019 Mar 14. pii: 10.1038/s41582-019-0168.
    PubMed     Text format    


    Neurology

  9. LEWIS A, Galetta S
    Editors' note: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2019;92:542.
    PubMed     Text format    

  10. KEARNEY H
    Reader response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2019;92:542-543.
    PubMed     Text format    

  11. BAR-OR A, Grove RA, Tolson JM, Derosier FJ, et al
    Author response: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
    Neurology. 2019;92:543.
    PubMed     Text format    

  12. YEH EA, Eshaghi A
    Evolution of regional brain atrophy in children with multiple sclerosis: Gray matters.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007254.
    PubMed     Text format    

  13. FOX RJ, Cosenza C, Cripps L, Ford P, et al
    A survey of risk tolerance to multiple sclerosis therapies.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007245.
    PubMed     Text format     Abstract available

  14. DE MEO E, Meani A, Moiola L, Ghezzi A, et al
    Dynamic gray matter volume changes in pediatric multiple sclerosis: A 3.5-year MRI study.
    Neurology. 2019 Mar 13. pii: WNL.0000000000007267.
    PubMed     Text format     Abstract available

  15. KALINCIK T
    Effectiveness of oral multiple sclerosis therapies in clinical context.
    Neurology. 2019 Mar 15. pii: WNL.0000000000007300.
    PubMed     Text format    


    PLoS One

  16. GIROLAMO F, Errede M, Longo G, Annese T, et al
    Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice.
    PLoS One. 2019;14:e0213508.
    PubMed     Text format     Abstract available

  17. KALKOWSKI L, Malysz-Cymborska I, Golubczyk D, Janowski M, et al
    MRI-guided intracerebral convection-enhanced injection of gliotoxins to induce focal demyelination in swine.
    PLoS One. 2018;13:e0204650.
    PubMed     Text format     Abstract available

  18. UGARTE-BERZAL E, Berghmans N, Boon L, Martens E, et al
    Gelatinase B/matrix metalloproteinase-9 is a phase-specific effector molecule, independent from Fas, in experimental autoimmune encephalomyelitis.
    PLoS One. 2018;13:e0197944.
    PubMed     Text format     Abstract available


    Rev Neurol

  19. PEREZ-ALVAREZ AI, Garcia-Rua A, Suarez-Santos P, Castanon-Apilanez M, et al
    [Appraisal of cerebral atrophy in multiple sclerosis by means of the corpus callosum index. Reply].
    Rev Neurol. 2019;68:269-270.
    PubMed     Text format    

  20. VALENCIA-CALDERON C
    [Appraisal of cerebral atrophy in multiple sclerosis by means of the corpus callosum index].
    Rev Neurol. 2019;68:268-269.
    PubMed     Text format    

  21. MAIA C, Costa A, Abreu P, Sa MJ, et al
    All-cause hospitalizations in multiple sclerosis patients.
    Rev Neurol. 2019;68:229-235.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: